KRAS and non-small cell lung carcinoma: Previously, we showed that bone metastases were more frequent in patients with EGFR+ metastatic NSCLC than in patients with KRAS+ or EGFR/KRAS wildtype NSCLC, and that post bone metastases survival was significantly longer in patients with EGFR+ NSCLC (1, 14).